MARKET

CNCE

CNCE

Concert Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.09
-0.43
-6.60%
After Hours: 6.09 0 0.00% 16:00 10/18 EDT
OPEN
6.52
PREV CLOSE
6.52
HIGH
6.61
LOW
6.02
VOLUME
199.18K
TURNOVER
--
52 WEEK HIGH
17.83
52 WEEK LOW
5.36
MARKET CAP
144.94M
P/E (TTM)
-1.8205
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CNCE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CNCE News

  • Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV 2019
  • Benzinga.6d ago
  • Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress
  • Business Wire.6d ago
  • The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck
  • Benzinga.10/06 21:15
  • Concert Pharmaceuticals (CNCE) Investor Presentation - Slideshow
  • Seeking Alpha - Article.10/04 17:56

More

Industry

Biotechnology & Medical Research
-1.17%
Pharmaceuticals & Medical Research
-0.94%

Hot Stocks

Name
Price
%Change

About CNCE

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
More

Webull offers Concert Pharmaceuticals Inc (CNCE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.